Myeloablative conditioning.
| Author, ref . | N . | Conditioning . | Age, y (range) . | HLA SIB/other donor . | Chemo-sensitive, % . | Median follow-up, mo . | PFS, % . | OS, % . | TRM, % . | Relapse, % . | cGVHD, % . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PFS indicates progression-free survival; OS, overall survival; TRM, treatment-related mortality; cGVHD, chronic graft-versus-host disease; TBI, total body irradiation; Cy, cyclophosphamide; Bu, busulfan; MEL, melphalan; NS, not stated specifically | |||||||||||
| *Four T cell–depleted transplants | |||||||||||
| Van Besien1 | 10 | TBI | 37 (23–45) | 10/0 | 0 | 72 | 70 | 80 | 20 | 0 | 50 |
| Van Besien6 | 113 | TBI 84% Non-TBI 16% | 38 (15–61) | 113/0 | 63 | 25 | 49 | 49 | 40 | 16 | – |
| Van Besien6 | 176 | TBI 68% Non-TBI 32% | 42 (22–64) | 100%/0 | 67 | 36 | 45 | 51 | 30 | 21 | 24 |
| Hari28 | 120 | TBI 75% Non-TBI 25% | 44 (22–70) | 100% | 72 | 50 | 67 | 71 | 25 | 8 | 46 |
| Stein5 | 15 | Cy/TBI 93% | 43 (31–50) | 95/5 | 95 | 60 | NS | 15 | 53 | 33 | – |
| Peniket7 | 231 | Various | 39 (19–66) | 96%/4% | 80 | 60 | 43 | 51 | 38 | 25 | – |
| Toze3 | 26 | Various* | 42 (20–52) | 20/6 | 46 | 29 | 54 | 58 | 30 | 18 | 54 |
| Forrest4 | 24 | Bu/Cy±MEL 92% | 44 (33–52) | 23/3 | 96 | 28 | 78 | 78 | 21 | 0 | 45 |
| Kuruvilla9 | 37 | BuCy | 43 (22–58) | 81%/19% | 89 | 65 | 79 | 76 | 16 | 3 | 54 |
| Author, ref . | N . | Conditioning . | Age, y (range) . | HLA SIB/other donor . | Chemo-sensitive, % . | Median follow-up, mo . | PFS, % . | OS, % . | TRM, % . | Relapse, % . | cGVHD, % . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PFS indicates progression-free survival; OS, overall survival; TRM, treatment-related mortality; cGVHD, chronic graft-versus-host disease; TBI, total body irradiation; Cy, cyclophosphamide; Bu, busulfan; MEL, melphalan; NS, not stated specifically | |||||||||||
| *Four T cell–depleted transplants | |||||||||||
| Van Besien1 | 10 | TBI | 37 (23–45) | 10/0 | 0 | 72 | 70 | 80 | 20 | 0 | 50 |
| Van Besien6 | 113 | TBI 84% Non-TBI 16% | 38 (15–61) | 113/0 | 63 | 25 | 49 | 49 | 40 | 16 | – |
| Van Besien6 | 176 | TBI 68% Non-TBI 32% | 42 (22–64) | 100%/0 | 67 | 36 | 45 | 51 | 30 | 21 | 24 |
| Hari28 | 120 | TBI 75% Non-TBI 25% | 44 (22–70) | 100% | 72 | 50 | 67 | 71 | 25 | 8 | 46 |
| Stein5 | 15 | Cy/TBI 93% | 43 (31–50) | 95/5 | 95 | 60 | NS | 15 | 53 | 33 | – |
| Peniket7 | 231 | Various | 39 (19–66) | 96%/4% | 80 | 60 | 43 | 51 | 38 | 25 | – |
| Toze3 | 26 | Various* | 42 (20–52) | 20/6 | 46 | 29 | 54 | 58 | 30 | 18 | 54 |
| Forrest4 | 24 | Bu/Cy±MEL 92% | 44 (33–52) | 23/3 | 96 | 28 | 78 | 78 | 21 | 0 | 45 |
| Kuruvilla9 | 37 | BuCy | 43 (22–58) | 81%/19% | 89 | 65 | 79 | 76 | 16 | 3 | 54 |